Venkat Mocherla

I do think that the back office tends to get more involved. um traction early on for companies because frankly it's just less risky that you're willing to and it's sort of a no-brainer nobody wants to do more add more administrative cost to the system. I think if anything, they want to make it more efficient and sort of reduce the cost ultimately to the patient.

I do think that the back office tends to get more involved. um traction early on for companies because frankly it's just less risky that you're willing to and it's sort of a no-brainer nobody wants to do more add more administrative cost to the system. I think if anything, they want to make it more efficient and sort of reduce the cost ultimately to the patient.

And so I think you're seeing, again, a resurgence in areas like revenue cycle. You're seeing call center optimization happening. You're seeing companies like Midstream think about

And so I think you're seeing, again, a resurgence in areas like revenue cycle. You're seeing call center optimization happening. You're seeing companies like Midstream think about

the financial um decisioning and how we can sort of uh you know help save frankly dollars to the health system and ultimately make the system a lot lower in cost now i do think like you know i mentioned in the clinical area and clinical operations um whether it's aspects like um you know throughput and length of stay management whether it's

the financial um decisioning and how we can sort of uh you know help save frankly dollars to the health system and ultimately make the system a lot lower in cost now i do think like you know i mentioned in the clinical area and clinical operations um whether it's aspects like um you know throughput and length of stay management whether it's

You know, your scribing technology, there's just been a vast array of applications, but there is a different pathway. And this is now we're talking about the hospital area, but obviously there's payers, there's life sciences are applying AI for drug discovery, likes of In-Citro, etc., There's, Matt, the intersection of technologies like AI with CRISPR.

You know, your scribing technology, there's just been a vast array of applications, but there is a different pathway. And this is now we're talking about the hospital area, but obviously there's payers, there's life sciences are applying AI for drug discovery, likes of In-Citro, etc., There's, Matt, the intersection of technologies like AI with CRISPR.

And so there's a bunch of applications even outside of the hospital ecosystem that I'm most familiar with that is equally and incredibly exciting.

And so there's a bunch of applications even outside of the hospital ecosystem that I'm most familiar with that is equally and incredibly exciting.

Yeah, I think, you know, the hardest kind of knock on healthcare is, you know, when you think about how risk averse the market is, and we think about And for the right reasons, right, for obvious reasons, the sale cycles tend to be really long, right? The average sale cycle for a health system is probably around 18 to 24 months.

Yeah, I think, you know, the hardest kind of knock on healthcare is, you know, when you think about how risk averse the market is, and we think about And for the right reasons, right, for obvious reasons, the sale cycles tend to be really long, right? The average sale cycle for a health system is probably around 18 to 24 months.

What's happened now, Scott, is I think there's a bunch of entrepreneurs not only going after health systems because I think people are curious and genuinely they want to, you know, solve some of these problems, but there's also a tremendous amount of interest now in the SMB and mid-market. So how do you help your three-practice physician, you know, three-doc practice, excuse me,

What's happened now, Scott, is I think there's a bunch of entrepreneurs not only going after health systems because I think people are curious and genuinely they want to, you know, solve some of these problems, but there's also a tremendous amount of interest now in the SMB and mid-market. So how do you help your three-practice physician, you know, three-doc practice, excuse me,

um you know because they don't have the kind of frankly thought structure to dictate having a receptionist and having a very advanced revenue cycle suite etc but now you can actually use ai to help you you know create a you know sort of like you know this is this is the era if you know some have said that they are abundant which i tend to agree with that which is how do you give these magical superpowers and and um people behind the scenes

um you know because they don't have the kind of frankly thought structure to dictate having a receptionist and having a very advanced revenue cycle suite etc but now you can actually use ai to help you you know create a you know sort of like you know this is this is the era if you know some have said that they are abundant which i tend to agree with that which is how do you give these magical superpowers and and um people behind the scenes

to go operate, whether your cost structure before, you had to be a giant health system to go do that. So that's the one area which is like just new markets opening up, which is quite an interesting and exciting trend.

to go operate, whether your cost structure before, you had to be a giant health system to go do that. So that's the one area which is like just new markets opening up, which is quite an interesting and exciting trend.

The second piece is, look, for obvious reasons, there's an entire disconnect that happens between all these stakeholders, between the patient and the provider, between the provider and the payer, between the payer and life sciences. And I think what we're seeing now are people who are

The second piece is, look, for obvious reasons, there's an entire disconnect that happens between all these stakeholders, between the patient and the provider, between the provider and the payer, between the payer and life sciences. And I think what we're seeing now are people who are